A patient with recalcitrant oral pemphigus vulgaris successfully treated with a biologic drug- Rituximab
Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease affecting mucous membranes and the skin. Rituximab (RTX), a monoclonal antibody against CD20, has been approved by FDA for the treatment of adults with moderate to severe PV. A 42-year-old Indian woman, previously diagnosed with oral...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Online |
| Kieli: | englanti |
| Julkaistu: |
International Association for Dental Research (Nigeria Division)
2019
|
| Linkit: | https://ajoh.oauife.edu.ng/index.php/ajoh/article/view/41 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Lisää ensimmäinen kommentti!